EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Evommune, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.27+0.10 (+1.93%)
Close on Oct 19, 2026
- Market cap
- $190.43M
- P/E (TTM)
- –
- Dividend yield
- –
Community
Notes and questions about Evommune from other investors
No posts about EVMN yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.